National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

NCPE assessment process
Ongoing
Rapid review received 28/06/2017
Rapid review completed 10/08/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 06/09/2017
Pre-submission consultation with applicant 23/10/2017
Submission received from applicant 22/01/2018
Preliminary review sent to applicant 25/04/2018
NCPE assessment re-commenced 15/06/2018
Preliminary review II sent to applicant 13/07/2018
Current Status Awaiting applicant response